---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: APC-003"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: APC-003. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 30 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence/apc-003"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: APC-003

<a id="heading-3.1.7"></a>

## 3.1.7 APC-003

<a id="heading-3.1.7.1"></a>

### 3.1.7.1 Objective

<a id="topic-3.1.7.1-1"></a>

#### Contribution of each component to the efficacy of AD109

> “Phase 2 Randomized Double-Blind Placebo-Controlled 4-Period Single-Dose Crossover Factorial Study to Evaluate the Contribution of the Individual Drug Components to the Efficacy of AD109 in Obstructive Sleep Apnea”
> “This is a randomized, 4-period, placebo-controlled, crossover, phase 2 clinical study to examine the efficacy and safety of AD109 versus its individual components or placebo in patients with obstructive sleep apnea.”

Source: [ClinicalTrials.gov NCT04580394](https://clinicaltrials.gov/study/NCT04580394)

<a id="topic-3.1.7.1-2"></a>

#### Objective as described by the company

> “We initiated APC-003, a Phase 2 clinical trial, in 2020, designed to demonstrate the individual contribution of aroxybutynin and atomoxetine to the efficacy of AD109.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.7.2"></a>

### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

#### Registered study dates

| Field | Quoted record |
| --- | --- |
| Study start (actual) | “2020-10-27” |
| Primary completion (actual) | “2021-05-28” |

Source: [ClinicalTrials.gov NCT04580394](https://clinicaltrials.gov/study/NCT04580394)

<a id="topic-3.1.7.2-2"></a>

#### Seven United States sites

> “APC-003 was a Phase 2 double-blind, placebo-controlled single dose crossover clinical trial with 60 participants conducted at seven sites in the United States.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.7.3"></a>

### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

#### Four-period single-dose randomized crossover

> “The study is a four-period single-dose randomized crossover design in which patients will undergo overnight polysomnographic (PSG) testing with dosing of one of the following 4 treatments: AD109, atomoxetine, R-oxybutynin or placebo.”
> “Participants will return 2 weeks after their final crossover PSG for an end of study (EOS) visit.”

Source: [ClinicalTrials.gov NCT04580394](https://clinicaltrials.gov/study/NCT04580394)

<a id="topic-3.1.7.3-2"></a>

#### Double-blind crossover with one-week washouts and no replacement of withdrawals

> “This was a double-blind, single dose crossover study.”
> “Overall study duration was up to 14 weeks. Participants who withdrew from the study were not replaced.”
> “Each participant received single doses of each of the four treatments, the order in which each treatment was assigned was random.”
> “Washout (One Week)”

Source: [ClinicalTrials.gov NCT04580394 results](https://clinicaltrials.gov/study/NCT04580394?tab=results)

<a id="topic-3.1.7.3-3"></a>

#### Four-week open-label extension

> “APC-003-OLE was a four-week OLE trial of APC-003.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.7.4"></a>

### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

#### Registered inclusion: age and AHI

> “Male or Female, between 25 to 65 years of age, inclusive, at the Screening Visit.”
> “AHI 10 to <20, or AHI ≥20 if meets other PSG criteria”

Source: [ClinicalTrials.gov NCT04580394](https://clinicaltrials.gov/study/NCT04580394)

<a id="topic-3.1.7.4-2"></a>

#### Registered exclusion: cardiac disease, hypertension, and CPAP use

> “Clinically significant cardiac disease (e.g., rhythm disturbances, coronary artery disease or cardiac failure) or hypertension requiring more than 2 medications for control.”
> “CPAP should not be used for at least 2 weeks prior to first study PSG”

Source: [ClinicalTrials.gov NCT04580394](https://clinicaltrials.gov/study/NCT04580394)

<a id="topic-3.1.7.4-3"></a>

#### Inclusion and exclusion as described by the company: AHI 10 to 45 events/h and low upper airway collapsibility

> “Patients between 25 and 65 years were included if they showed an AHI between ten and 45 events per hour.”
> “Patients with AHI under 45 could be randomized only if they showed signs of low upper airway collapsibility, including mean desaturation of oxygen related to upper airway obstruction less than 8% and prevalence of hypopneas over apneas.”
> “Main exclusion criteria were a history of insomnia or narcolepsy, craniofacial malformations, clinically significant cardiac disease (coronary artery disease, heart failure, rhythm disturbances), psychiatric or neurologic diseases, constipation or urinary retention.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.7.5"></a>

### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

#### Four single-dose treatments in oral capsules

> “Oral capsules were administered before sleep in random order of each of the following: AD109 (Treatment A: Atomoxetine 75 mg and R-Oxbutynin 2.5 mg), Treatment B: Atomoxetine 75 mg and Placebo, Treatment C:R-Oxbutynin 2.5 mg and placebo, Treatment D:Placebo and Placebo.”

Source: [ClinicalTrials.gov NCT04580394 results](https://clinicaltrials.gov/study/NCT04580394?tab=results)

<a id="topic-3.1.7.5-2"></a>

#### Doses as described by the company, crossover and open-label extension

> “Participants were dosed with AD109 (2.3mg aroxybutynin and 75mg atomoxetine), atomoxetine alone (75mg), aroxybutynin alone (2.3mg) or placebo.”
> “Of the 60 participants in APC-003, 37 participated in the OLE and received AD109 for one week at the run-in dose of 2.3mg aroxybutynin and 37.5mg atomoxetine, followed by three weeks of AD109 at the target dose of 2.3mg aroxybutynin and 75mg atomoxetine.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.7.6"></a>

### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

#### 3.1.7.6.1 Rationale for Using Hypoxic Burden as the Primary Endpoint

<a id="topic-3.1.7.6.1-1"></a>

##### Registered primary outcome: change in log10 hypoxic burden, events with 4% or greater desaturation

> “Change in Hypoxic Burden (HB) Log10HB[(%*Min)/Hour]”
> “Change in Hypoxic Burden (HB) is calculated as the oxygen desaturation 'area under the curve' in association with individual apneas and hypopneas.”
> “Events with 4% or greater desaturations were included in the calculation of HB.”
> “1 night (treatment duration) (0-8 hours collected continuously)”

Source: [ClinicalTrials.gov NCT04580394](https://clinicaltrials.gov/study/NCT04580394)

<a id="topic-3.1.7.6.1-2"></a>

##### Primary and key secondary endpoints as described by the company

> “The primary endpoint of the trial was reduction of HB and AHI was a key secondary efficacy endpoint.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.7.6.1-3"></a>

##### Company rationale for oxygenation measures alongside AHI

> “There are additional measures of oxygen levels that measure the amount of insufficient oxygen levels over time, such as the Oxygen Desaturation Index (ODI) or HB, which may provide additional insight into potential benefit on serious cardiovascular problems that develop or worsen over time.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.7.6.1-4"></a>

##### Other registered assessment: Digit Symbol Substitution Test

> “a neuropsychological test sensitive to brain damage, dementia, age and depression where numbers are assigned symbols.”
> “The number of correct symbols within the allowed time is measured.”

Source: [ClinicalTrials.gov NCT04580394](https://clinicaltrials.gov/study/NCT04580394)

<a id="heading-3.1.7.7"></a>

### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

#### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

##### Enrolled and analyzed participants in the registry

| Field | Quoted record |
| --- | --- |
| Enrollment (actual) | “Enrollment (Actual) 60” |
| Participants analyzed for the primary outcome | “Fifty-nine (98.3%) participants were included in the mITT Population” |

Source: [ClinicalTrials.gov NCT04580394 results](https://clinicaltrials.gov/study/NCT04580394?tab=results)

<a id="heading-3.1.7.7.2"></a>

#### 3.1.7.7.2 Description of Analysis Sets

<a id="topic-3.1.7.7.2-1"></a>

##### Modified intention-to-treat set for efficacy and safety reporting by treatment

> “The efficacy was analyzed using the mITT Set comprised of all participants who took at least 1 dose of any of the study treatments and had at least 1 measurement for the primary endpoint.”
> “The study analysis did not analyze data by period. AEs were reported for the safety analysis by number and percent for treatment group only.”

Source: [ClinicalTrials.gov NCT04580394 results](https://clinicaltrials.gov/study/NCT04580394?tab=results)

<a id="heading-3.1.7.8"></a>

### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

#### 3.1.7.8.1 Participant Disposition

<a id="topic-3.1.7.8.1-1"></a>

##### Screening, randomization, and participant flow by period

> “Seven clinical sites screened 146 participants, 60 participants were randomized.”

Source: [ClinicalTrials.gov NCT04580394 results](https://clinicaltrials.gov/study/NCT04580394?tab=results)

<a id="topic-3.1.7.8.1-2"></a>

##### Participants starting and completing each period, with reasons for not completing

| Period | Started | Completed | Reasons not completed |
| --- | --- | --- | --- |
| First intervention | “Started 60” | “Completed 57” | “Incorrectly Randomized 1 Lost to Follow-up 1 Physician Decision 1” |
| Second intervention | “Started 56” | “Completed 56” | “Not Completed 0” |
| Fourth intervention | “Started 49” | “Completed 49” | “Not Completed 0” |

Source: [ClinicalTrials.gov NCT04580394 results](https://clinicaltrials.gov/study/NCT04580394?tab=results)

<a id="topic-3.1.7.8.1-3"></a>

##### Open-label extension participation

> “Of the 60 participants in APC-003, 37 participated in the OLE”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.7.8.2"></a>

#### 3.1.7.8.2 Baseline Characteristics

<a id="topic-3.1.7.8.2-1"></a>

##### Registry baseline characteristics

| Characteristic | All study participants (n = 60) |
| --- | --- |
| Sex | “Female 25 Male 35” |
| Ethnicity | “Hispanic or Latino 16 Not Hispanic or Latino 44” |
| Race | “Asian 1 Native Hawaiian or Other Pacific Islander 0 Black or African American 11 White 47 More than one race 1” |
| Body mass index, median (full range), kg/m^2 | “33 (22 to 39)” |

Source: [ClinicalTrials.gov NCT04580394 results](https://clinicaltrials.gov/study/NCT04580394?tab=results)

<a id="topic-3.1.7.8.2-2"></a>

##### Baseline AHI with 4% desaturation criterion as reported by the company

> “Median baseline AHI (with hypopneas scored when associated with a four percent or greater reduction in SpO2 from baseline) was 29.6 events per hour with an interquartile range of 18.8 to 43.6, a severity range that is typically classified as moderate to severe OSA.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.7.8.3"></a>

#### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

##### Registry primary outcome: least squares mean change in log10 hypoxic burden (95% confidence interval), events with 4% or greater desaturation, mITT

| Treatment | Log10HB4%[%min/hour] |
| --- | --- |
| AD109 (n = 59) | “-0.41 (-0.54 to -0.28)” |
| Atomoxetine (n = 59) | “-0.36 (-0.49 to -0.23)” |
| R-oxybutynin (n = 59) | “-0.04 (-0.17 to 0.09)” |
| Placebo (n = 59) | “-0.06 (-0.18 to 0.07)” |

Source: [ClinicalTrials.gov NCT04580394 results](https://clinicaltrials.gov/study/NCT04580394?tab=results)

<a id="topic-3.1.7.8.3-2"></a>

##### Hypoxic burden and AHI4 on the first night and at week 4 of the open-label extension, as reported in the company prospectus

> “The results of these trials demonstrated a 44% reduction (p<0.0001) of HB on the first night of administration of AD109 vs placebo which persisted and actually increased to 65% reduction at week four (p=0.002), suggesting no reduction of clinical activity over time.”
> “Findings for AHI were of similar magnitude, with a 34% reduction (p=0.001) on the first night which increased to 56% reduction (p=0.0245) after four weeks of treatment.”
> “The four-week duration of the OLE also demonstrated the durability of clinical activity over four weeks compared to prior studies over one day.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.7.8.4"></a>

#### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.7.8.4-1"></a>

##### Simplified Sleep Apnea Quality of Life Index versus baseline, as reported in the company prospectus

> “OSA symptoms showed statistically significant improvement vs baseline for a simplified version of the Sleep Apnea Quality of Life Index (SAQLI) (p=0.0027), particularly components measuring symptoms of daytime tiredness, waking unrefreshed and bothersome snoring.”
> “The median SAQLI at baseline was 23.0 and decreased to 16.0 at Visit 3, i.e. a 30.4% decrease in SAQLI.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.7.8.5"></a>

#### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

##### Registry adverse events: deaths, serious adverse events, and other adverse events at a 3% threshold

| Event | A: AD109 | B: Atomoxetine 75 mg + placebo | C: R-oxybutynin 2.5 mg + placebo | D: Placebo + placebo |
| --- | --- | --- | --- | --- |
| All-cause mortality | “0/56 (0.00%)” | “0/54 (0.00%)” | “0/54 (0.00%)” | “0/57 (0.00%)” |
| Serious adverse events, total | “1/56 (1.79%)” | “0/54 (0.00%)” | “0/54 (0.00%)” | “0/57 (0.00%)” |
| Atrial fibrillation (serious) | “1/56 (1.79%)” | “0/54 (0.00%)” | “0/54 (0.00%)” | “0/57 (0.00%)” |
| Seizure (serious) | “1/56 (1.79%)” | “0/54 (0.00%)” | “0/54 (0.00%)” | “0/57 (0.00%)” |
| Gastroesophageal reflux disease | “2/56 (3.57%)” | “2/54 (3.70%)” | “0/54 (0.00%)” | “0/57 (0.00%)” |

Source: [ClinicalTrials.gov NCT04580394 results](https://clinicaltrials.gov/study/NCT04580394?tab=results)

<a id="topic-3.1.7.8.5-2"></a>

##### Single-night crossover: adverse events, withdrawals, and the serious adverse event, as described by the company

> “During the 1-night APC-003 study, the only TEAE occurring in at least two trial participants in a single study arm was gastroesophageal reflux, which occurred in two (3.6%) participants treated with AD109 and two (3.7%) participants treated with atomoxetine 75mg alone.”
> “Two participants withdrew from the study due to AEs (namely pleurisy with elevated white blood cells and”
> “atrial fibrillation), but these AEs were considered to be unrelated to the study drug.”
> “One participant experienced an SAE of possible seizure vs arrhythmia/atrial fibrillation, but because the participant had a previously undisclosed history of arrhythmia with differential diagnosis of seizure, and implantation of a cardiac loop recorder to aid in ongoing efforts to diagnose the condition, the event was considered to be unrelated to the drug.”
> “No drug-related SAEs occurred in the trial.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="topic-3.1.7.8.5-3"></a>

##### Four-week open-label extension: adverse events

> “In the four-week OLE study, the most frequently reported TEAEs occurring in at least two study participants were insomnia (six (16.2%) participants), nausea (three (8.1%) participants), pollakiuria (two (5.4%) participants), and urinary hesitation (two (5.4%) participants).”
> “No serious TEAEs, severe AEs or deaths were reported.”

Source: [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

<a id="heading-3.1.7.9"></a>

### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

#### Summary

- Publication status: results are available only from the registry record and the company prospectus.
- Design: four-period single-dose crossover with one-week washouts; participants who withdrew were not replaced, and 49 participants started the fourth period. The registry states the analysis did not analyze data by period and reported adverse events by treatment group only.
- Eligibility differs by source: the registry states AHI 10 to below 20, or 20 or more if other polysomnography criteria were met, while the prospectus states AHI 10 to 45 events/h with randomization limited to participants showing signs of low upper airway collapsibility. Ages were 25 to 65, and exclusions included a history of insomnia and clinically significant cardiac disease.
- Open-label extension: 37 of 60 participants received AD109 for 4 weeks without a control group; the reported reductions in hypoxic burden and AHI at week 4 and the SAQLI change versus baseline come from the prospectus.
- Withdrawals differ by source: the registry lists first-period non-completion as incorrectly randomized, lost to follow-up, and physician decision (1 each), while the prospectus states two participants withdrew because of adverse events (pleurisy and atrial fibrillation).
- Safety: one serious adverse event (possible seizure versus arrhythmia or atrial fibrillation) occurred with AD109 in a participant with a previously undisclosed history of arrhythmia and was considered unrelated to the drug.
- Sponsor: the prospectus describes APC-003 as a trial the company initiated.

Source: [ClinicalTrials.gov NCT04580394](https://clinicaltrials.gov/study/NCT04580394); [ClinicalTrials.gov NCT04580394 results](https://clinicaltrials.gov/study/NCT04580394?tab=results); [Apnimed prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1745648/000119312526328422/apmd_424b4.htm)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
